BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
June 01, 2023 09:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
May 08, 2023 07:00 ET
|
BioRestorative Therapies, Inc
New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjectsLeverage...
BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
March 07, 2023 06:30 ET
|
BioRestorative Therapies, Inc
Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of...
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
March 02, 2023 07:30 ET
|
BioRestorative Therapies, Inc
--Notice of allowance will be the third US patent to issue from this ThermoStem® family targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., March 02, 2023 ...
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
November 16, 2022 08:56 ET
|
BioRestorative Therapies, Inc
Melville, NY., Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of...
Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 09:30 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 on target to complete enrollment by SeptemberExpanded efforts to increase enrollment in PCS499 and PCS6422 showing results HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa...
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
March 30, 2022 16:00 ET
|
Processa Pharmaceuticals, Inc.
Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing...
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
February 16, 2022 08:30 ET
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
January 26, 2022 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet...
Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
November 11, 2021 16:05 ET
|
Processa Pharmaceuticals, Inc.
Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...